Your session is about to expire
← Back to Search
Ibrutinib for T-Cell Lymphoma
Study Summary
This trial is testing a new drug, ibrutinib, to see if it's safe for patients with T-cell non-Hodgkin lymphoma that has either come back or not responded to treatment.
- T-Cell Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 201 Patients • NCT03053440Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you provide an overview of the research conducted regarding Ibrutinib?
"Ibrutinib first emerged as a medicinal compound in 2011, when the National Institutes of Health Clinical Center initiated its clinical trials on this drug. Since then, 97 studies have been completed and 155 active investigations are underway - many of which originate from New york City."
What is the current size of enrollment for this trial?
"Presently, this clinical trial is not seeking new patients. The first posting of the study was on January 1st 2015 and it has been updated most recently on November 8th 2022. If you are looking for alternative trials, there exist 1733 studies recruiting t-cell lymphoma patients and 155 medical studies with open enrollment for Ibrutinib treatments."
Are any additional participants being admitted for this scientific experiment?
"According to the clinicaltrials.gov database, this medical trial is not currently recruiting patients. This study was initially posted on January 1st 2015 and last edited November 8th 2022; however, there are 1888 alternative studies actively seeking participants at present."
Is Ibrutinib a potentially hazardous treatment option?
"There is sparse clinical evidence demonstrating the safety and efficacy of Ibrutinib, so it has been rated a 1 on our team's scale."
Share this study with friends
Copy Link
Messenger